Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023;239(3):462-477.
doi: 10.1159/000529220. Epub 2023 Jan 19.

Intralesional Corticosteroid Administration in the Treatment of Keloids: A Scoping Review on Injection Methods

Affiliations

Intralesional Corticosteroid Administration in the Treatment of Keloids: A Scoping Review on Injection Methods

Qi Yin et al. Dermatology. 2023.

Abstract

Background: Intralesional corticosteroid administration (ICA) is a first-line treatment for keloids. However, its clinical results are still highly variable and often suboptimal. Treatment results may strongly be influenced by various operator-dependent factors. The aim of this study was to map the details of ICA in keloids described in randomized controlled trials (RCTs), hence presenting the scientific practice of a first-line treatment for keloids in the best available evidence.

Summary: A systematic search was performed on PubMed, Ovid MEDLINE, Ovid EMBASE, and CENTRAL. Eligible studies were RCTs including patients with keloids treated with intralesional corticosteroids. Treatment and study design-related data were charted on a predefined form. Thirty-eight RCTs were included for data extraction. Triamcinolone acetonide was used in 37 (97.4%) studies. Dosing per cm2 could only be compared among ten (26%) studies and varied from 1 to 20 mg. The maximum dose per session varied from 20 to 80 mg. Local anesthetics were administered in seven (20%) RCTs. Treatment intervals varied from weekly to monthly, with 4 weeks most frequently (50%) used. Needle size was reported in eleven (29%) studies and varied from 26 to 30-gauge. Syringe size was specified in four (11%) studies, being 1 mL. The injection level was described in eleven (29%) studies. Blanching as endpoint was reported in ten (26%) studies. Outcome measures varied widely, from height, surface area, or volume, to Vancouver Scar Scale, Patient and Observer Scar Assessment Scale, pain and itch scores, patient satisfaction, and different efficacy rates. Only six studies had a follow-up of ≥6 months. Recurrence was identified in two studies with 18 weeks and 1 year of follow-up. Adverse events were reported in 23 (61%) studies.

Keywords: Corticosteroid; Injection; Intralesional corticosteroids; Keloid; Triamcinolone.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Fig. 1
Fig. 1
Flow diagram of the study selection process.
Fig. 2
Fig. 2
Risk of bias of the included RCTs. The large majority of articles (76%) were judged as having a high risk of bias. Measurement of outcome was most frequently judged as having a high risk of bias (47.4%), followed by deviations from intended intervention (26.3%) and missing outcome data (26.3%), randomization process (23.7%), and selection of reported result (18.4%).
Fig. 3
Fig. 3
a Pascal's law. If the diameter of a syringe plunger doubles or triples, the created pressure using the same force will decrease four and nine times, respectively. b Poiseuille's law. The gauge pressure needed to be produced using a 30-gauge needle (inner radius: 0.080 mm) would be approximately six times that of using a 26-gauge needle (inner radius: 0.125 mm) of the same length.

References

    1. Ogawa R. Keloid and hypertrophic scars are the result of chronic inflammation in the reticular dermis. Int J Mol Sci. 2017;18((3)):606. - PMC - PubMed
    1. Furtado F, Hochman B, Ferrara SF, Dini GM, Nunes JMC, Juliano Y, et al. What factors affect the quality of life of patients with keloids? Rev Assoc Med Bras. 2009;55((6)):700–704. - PubMed
    1. Bijlard E, Kouwenberg CAE, Timman R, Hovius SER, Busschbach JJV, Mureau MAM. Burden of keloid disease a cross-sectional health-related quality of life assessment. Acta Derm Venereol. 2017;97((2)):225–229. - PubMed
    1. Kassi K, Kouame K, Kouassi A, Allou A, Kouassi I, Kourouma S, et al. Quality of life in black African patients with keloid scars. Dermatol Rep. 2020;12((2)):8312. - PMC - PubMed
    1. Morelli Coppola M, Salzillo R, Segreto F, Persichetti P. Triamcinolone acetonide intralesional injection for the treatment of keloid scars patient selection and perspectives. Clin Cosmet Investig Dermatol. 2018;11:387–396. - PMC - PubMed

Publication types